

***Francisella tularensis* subsp. *holarctica*  
LVS R1 Antigen, Formalin-Inactivated****Catalog No. NR-15752**

This reagent is the tangible property of the U.S. Government.

**For research use only. Not for human use.****Contributor:**

National Institutes of Allergy and Infectious Diseases,  
National Institutes of Health

**Product Description:**

LVS R1 antigen was prepared by formalin inactivation of a suspension of *Francisella tularensis* subsp. *holarctica* (Type B), strain LVS R1. Strain LVS R1 is a mutant of the LVS<sup>1-4</sup> strain lacking the O-antigen.<sup>5</sup>

**Material Provided:**

Each vial contains approximately 1 mL of NR-15752 formulated in 0.05 M PBS, pH 7.2. The concentration is shown on the Certificate of Analysis for each lot.

**Packaging/Storage:**

NR-15752 is provided frozen on dry ice and should be stored at -70°C ± 10°C immediately upon arrival.

**Citation:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: *Francisella tularensis* subsp. *holarctica* LVS R1 Antigen, Formalin-Inactivated, NR-15752."

**Biosafety Level: 1**

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see [www.cdc.gov/od/ohs/biosfty/bmb15/bmb15toc.htm](http://www.cdc.gov/od/ohs/biosfty/bmb15/bmb15toc.htm).

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org).

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations

from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**References:**

1. Eigelsbach, H. T. and C. M. Downs. "Prophylactic Effectiveness of Live and Killed Tularemia Vaccines. I. Production of Vaccine and Evaluation in the White Mouse and Guinea Pig." J. Immunol. 87 (1961): 415-425. PubMed: 13889609.
2. Tigertt, W. D. "Soviet Viable *Pasteurella tularensis* Vaccines. A Review of Selected Articles." Bacteriol. Rev. 26 (1962): 354-373. PubMed: 13985026.
3. Sjöstedt, A. "Tularemia: History, Epidemiology, Pathogen Physiology, and Clinical Manifestations." Ann. N. Y. Acad. Sci. 1105 (2007): 1-29. PubMed: 17395726.
4. Oyston, P. C. F. and J. E. Quarry. "Tularemia Vaccine: Past, Present and Future." Antonie van Leeuwenhoek 87 (2005): 277-281. PubMed: 15928980.
5. Matthew Hinz, personal communication.

ATCC® is a trademark of the American Type Culture Collection.

